These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22957689)

  • 1. Regulatory T cells and other lymphocyte subpopulations in patients with melanoma developing interferon-induced thyroiditis during high-dose interferon-α2b treatment.
    Soldevila B; Alonso N; Martínez-Arconada MJ; Granada ML; Boada A; Vallejos V; Fraile M; Fernández-Sanmartín MA; Pujol-Borrell R; Puig-Domingo M; Sanmartí A; Martínez-Cáceres EM
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):621-8. PubMed ID: 22957689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study of lymphocyte subpopulations and regulatory T cells in patients with chronic hepatitis C virus infection developing interferon-induced thyroiditis.
    Soldevila B; Alonso N; Martínez-Arconada MJ; Granada ML; Baía D; Vallejos V; Fraile M; Morillas RM; Planas R; Pujol-Borrell R; Martínez-Cáceres EM; Sanmartí AM
    Clin Endocrinol (Oxf); 2011 Oct; 75(4):535-43. PubMed ID: 21592168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.
    Soldevila B; Alonso N; Martínez-Arconada MJ; Morillas RM; Planas R; Sanmartí AM; Martínez-Cáceres EM
    J Viral Hepat; 2011 Jun; 18(6):384-92. PubMed ID: 20487258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
    Mozzillo N; Ascierto P
    Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alpha treatment and thyroid dysfunction.
    Tomer Y; Blackard JT; Akeno N
    Endocrinol Metab Clin North Am; 2007 Dec; 36(4):1051-66; x-xi. PubMed ID: 17983936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
    Chevolet I; Schreuer M; Speeckaert R; Neyns B; Hoorens I; van Geel N; Krüse V; Hennart B; Allorge D; Van Gele M; Brochez L
    Melanoma Res; 2015 Aug; 25(4):357-61. PubMed ID: 26050145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
    Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
    J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological response in chronic hepatitis C virus infection during interferon alpha therapy.
    Panasiuk A; Prokopowicz D; Zak J
    Hepatogastroenterology; 2004; 51(58):1088-92. PubMed ID: 15239252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
    Moschos SJ; Edington HD; Land SR; Rao UN; Jukic D; Shipe-Spotloe J; Kirkwood JM
    J Clin Oncol; 2006 Jul; 24(19):3164-71. PubMed ID: 16809739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification.
    Mandac JC; Chaudhry S; Sherman KE; Tomer Y
    Hepatology; 2006 Apr; 43(4):661-72. PubMed ID: 16557537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
    Kirkwood JM; Richards T; Zarour HM; Sosman J; Ernstoff M; Whiteside TL; Ibrahim J; Blum R; Wieand S; Mascari R
    Cancer; 2002 Sep; 95(5):1101-12. PubMed ID: 12209697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B.
    Gogas H; Paterakis G; Frangia K; Bafaloukos D; Pectasides D; Kalofonos HP; Loukopoulos D; Stavropoulou-Giokas C; Ioannovich J; Mihm MC
    Am J Clin Oncol; 2002 Dec; 25(6):591-6. PubMed ID: 12478006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
    Dréau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL
    Oncol Res; 2000; 12(5):241-51. PubMed ID: 11417749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
    Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
    J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease.
    Treusch M; Vonthein R; Baur M; Günaydin I; Koch S; Stübiger N; Eckstein AK; Peter HH; Ness T; Zierhut M; Kötter I
    Rheumatology (Oxford); 2004 Oct; 43(10):1275-82. PubMed ID: 15252211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
    Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
    Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection.
    Tran HA; Reeves GE; Jones TL
    QJM; 2009 Feb; 102(2):117-22. PubMed ID: 19033352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional lymphocyte subset assessment of the Th1/Th2 profile in patients with autoimmune thyroiditis by flowcytometric analysis of peripheral lymphocytes.
    Colin IM; Isaac J; Dupret P; Ledant T; D'Hautcourt JL
    J Biol Regul Homeost Agents; 2004; 18(1):72-6. PubMed ID: 15323363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
    Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
    Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
    Massanella M; Tural C; Papagno L; Garcia E; Jou A; Bofill M; Autran B; Clotet B; Blanco J
    Antivir Ther; 2010; 15(3):333-42. PubMed ID: 20516553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.